The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Many high risk, high reward medical therapies that use cutting edge science are proving themselves in clinical trials. But are health services ready to pay for them—and how? Marianne Guenot reports On ...

Vertex Pharmaceuticals Incorporated ... The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, ...

Under Reshma Kewalramani's leadership, Vertex achieved a major milestone with the FDA’s first-ever approval of a CRISPR-based ...

Kewalramani becme the first female CEO of a large, public U.S. biotechnology company after immigrating from India at age 11 ...

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a ...